Seattle, Washington 98122


The purpose of this study is to find out the effects (good and bad) of highly focused radiation on you and your prostate cancer. The purpose of this evaluation is to see if this treatment causes fewer side effects that other standard treatment approaches, and to evaluate the effect of this treatment on your prostate tumor and your quality of life over time.


Inclusion Criteria: - Histologically proven prostate adenocarcinoma - Clinical stage T1a-T3, N0-Nx, M0-Mx - Patients belonging in one of the following risk groups: (1) LOW RISK: CS T1a-T2a, Gleason 2-6, PSA<10, Nx-0, Mx-0; (2) INTERMEDIATE RISK: CS T2b, Gleason ≤7, PSA<20, Nx-0, Mx-0, or CS T1a-T2b, Gleason 2-6, PSA≥10 & <20, Nx-0, Mx-0, or CS T1a-T2b, Gleason 7, PSA≤20, Nx-0, Mx-0; or (3) HIGH RISK: CS T2c-T3, any Gleason, any PSA, or CS T1-3, Gleason ≥8 and/or PSA≥20 - Karnofsky performance status 70-100 - Hormone therapy: includes LHRH agonists (e.g. leuprolide, goserelin, triptorelin), antagonists (e.g. degarelix), peripheral blockers (e.g. flutamide, bicalutamide, nilutamide), estrogens (e.g. DES) and bilateral orchiectomy - Low and Intermediate risk groups: no hormone ablation for two months prior to enrollment, or during treatment - High risk group: three hormone therapy regimens are allowed - 5-alpha reductase inhibitors (e.g., finasteride or dutasteride) are allowed Exclusion Criteria: - Prior prostatectomy or cryotherapy of the prostate - Prior high-dose radiotherapy to the prostate or lower pelvis - Implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion



Primary Contact:

Principal Investigator
Robert Meier, MD
Swedish Medical Center Radiosurgery Center

Mary Monahan
Phone: (206) 320-7129

Backup Contact:

Robert Meier, MD
Phone: (206) 320-7130

Location Contact:

Seattle, Washington 98122
United States

Mary Monahan
Phone: 206-320-7029

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.